Vandria SA

Our CEO Klaus Dugi is on his way to San Francisco to attend attending the EBD Group Sara Jane Demy #BiotechShowcase 13-16 January. He is looking forward to catching up with colleagues from the life sciences and healthcare industry, and network with biotech and pharma industry colleagues and investors. We recently announced our transition to a clinical stage company with our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer for aging-related CNS disorders now in a Phase 1 trial and having closed our series A to fund initial trials – so plenty of news to share! We are already planning our series B to fund further trials and pipeline growth.  If you are in San Francisco and want to meet up send us a partnering invitation or email us on info@vandria.com More information on our science and portfolio HERE www.vandria.com #Partnering #Investment #LifeScienes #JPMHealthcare #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy

Thrilled to be part of the Vandria venture. Now a clinical stage biotech in the exciting fields of cell rejuvenation and healthspan!

Vandria SA begins clinical trials for promising mitophagy inducer First subjects dosed in first-in-human Phase 1 clinical trial of small molecule central nervous system compound for age-related diseases. Klaus Dugi #biotech

NEWS We are super excited that we have become a clinical stage company. Today we announced that the first subjects have been dosed in our first-in-human clinical trial of our lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.   VNA-318 is an orally available first-in-class small molecule against a novel target to rejuvenate cells and treat age-related diseases through a dual mode of action including the induction of mitophagy. It is being developed initially for patients with early-stage CNS and neurodegenerative disorders and is intended to improve cognition and limit memory loss progression.   Read the full press release HERE https://lnkd.in/eq4rG8uT   More information on our science and portfolio HERE www.vandria.com   #ClinicalTrial #NeuroDegenerativeDiseases #CognitiveDisorders #DrugDevelopment #Mitophagy  

Our CEO Klaus Dugi will be in San Francisco 12-16 January for the annual ‘JPM Week’ gathering of healthcare/life sciences executives and investors. He will be attending the EBD Group Demy-Colton #BiotechShowcase. He is looking forward to catching up with colleagues from the life sciences and healthcare industry, and network with biotech and pharma industry colleagues and investors. If you plan to be there and would like to meet up to hear about our progress with our mitophagy inducers, do get in touch. We’d be delighted to share our clinical development plans for our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer for aging-related CNS disorders and other indications. Having recently closed our series A to fund initial trials, we are already planning our series B to fund further trials and pipeline growth. To meet up send us a partnering invitation or email us on info@vandria.com More information on our science and portfolio HERE www.vandria.com #Partnering #Investment #LifeScienes #JPMHealthcare #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy

AWARDS DINNER Our CSO Pénélope Andreux is in London to attend the Informa LSX - partnering for Life Science eXecutives 2024 European Lifestars Awards - Celebrating Life Science Leaders dinner at the City Central @ Honourable Artillery Company where she is looking forward to networking with other finalists and colleagues from the life sciences industry. Pénélope was selected as a finalist in the Women Led Businesses Category. A key member of Vandria’s Executive Team, she is a mitochondrial expert, she leads our team developing first-in-class small molecule mitophagy inducers, capitalizing on 15 years of discovery science, to treat diseases of aging including neurological disorders. Competition is fierce – so good luck to Pénélope and the other finalists. The list of finalists can be viewed here - https://lnkd.in/dNeDbkCx #awards #leadership #drugdiscovery #healthyaging #neuroscience #mitophagy 

APPOINTMENT we are absolutely thrilled to welcome Professor Li-Huei Tsai to our team. A world recognised expert in #Alzheimer’s Research and brain aging she has agreed to become a consultant to Vandria. Currently Director of The Picower Institute for Learning and Memory and Professor of neuroscience in the MIT Brain and Cognitive Sciences, she has co-founded the Aging Brain Initiative and is co-director of the Alana Down Syndrome Center. A Fellow of the American Association for the Advancement of Science (AAAS) and National Academy of Inventors, and a Member of the National Academy of Medicine and the American Academy of Arts & Sciences, during her career she has received multiple awards and recognition for her outstanding contribution to neuroscience research and the biological mechanisms of aging. We look forward to her input and insights as we advance our first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Already our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer is about to enter the clinic for mild cognitive disorders. It has been shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. Find more information on our science and portfolio at www.vandria.com #MitochonrialTherapeutics #mitophagy #NeuroDegenerativeDiseases #DrugDevelopment #Innovation #Biotech #Aging

Our CEO Klaus Dugi and Head of BD and Finance Peter Harboe-Schmidt are preparing for Informa Connect #BioEurope in Stockholm 4-6 October. If you plan to be there and would like to meet up to hear about our progress with our mitophagy inducers, do get in touch. They will be looking forward to catching up with colleagues from the life sciences and healthcare industry, and network with biotech and pharma industry colleagues and investors. Our plans are well advanced to start clinical development in the coming weeks for our lead candidate, VNA-318, a brain-penetrant, patent-protected, mitophagy inducer and we are already planning our series B to fund further trials and pipeline growth. To meet up send us a partnering invitation or email us on info@vandria.com More information on our science and portfolio at www.vandria.com #Partnering #Investment #LifeScienes #MitochondrialTherapeutics #NeuroDegenerativeDiseases #DrugDevelopment #Mitophagy

Today is World Alzheimer’s Day. A day to celebrate recent advances in treatments for Alzheimer’s and to recognize the continuing need to develop new treatments for the >55million people worldwide and their families living with Alzheimer’s. Vandria is advancing a pipeline of first-in-class mitophagy inducers that rejuvenate cells through mitochondrial renewal. Often referred to as the powerhouse of the cell, mitochondria play a pivotal role in energy production and scientists have demonstrated links between mitochondrial dysfunction and neurological disorders, including Alzheimer’s. Our lead program, VNA-318 is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. It is on track to enter clinical trials in the coming weeks. If you’re intrigued by our science, you can find out more about our portfolio at www.vandria.com #WorldAlzheimersDay #Alzheimers #Parkinsons #PD #mitophagy #NeuroDegenerativeDiseases #DrugDevelopment #Innovation

AWARD NEWS Congratulations to our CSO Pénélope Andreux who has been selected as finalist in the LSX - partnering for Life Science eXecutives 2024 European Lifestars Awards - Celebrating Life Science Leaders Awards Informa. A mitochondrial expert, Pénélope lead our team developing first-in-class small molecule mitophagy inducers, capitalizing on 15 years of discovery science, to treat diseases of aging including neurological disorders. Pénélope orchestrated the company’s move this year to dedicated lab facilities at @Superlab Suisse on the Biopôle Lausanne campus. Under her leadership, the team generated compelling scientific data which attracted new investors, Hevolution Foundation and Dolby Family Ventures into our Series A financing joining our founding investor #NDCapital and bringing the total raised to $30.7M (CHF28.3M). She has also been instrumental in attracting non-dilutive grants from #Eurostars and Innosuisse totaling €3.8 M. Pénélope is a key member of Vandria’s Executive Team working alongside our CEO Klaus Dugi, MD to prepare our lead program, VNA-318 for our first-in-man clinical trial for cognitive decline, due to start later this year. Competition is fierce – so good luck to Pénélope and other finalists. Winners will be announced on Monday 18 November at the Awards Dinner in London. The list of finalist can be viewed here - https://lnkd.in/dNeDbkCx #awards #leadership #drugdiscovery #healthyaging #neuroscience #mitophagy